ChatGPT

Perplexity

Gemini

Claude

Grok

My Intuitive is a personalized portal that connects surgeons to Intuitive’s ecosystem of digital products and services. Whether you are a new or experienced user of the da Vinci surgical system, you c

The Intuitive Events app is your go-to resource for ISI events, keeping you informed with real-time schedules, important announcements, speaker details, and personalized agendas where available. Navig

Intuitive 3D Models app is used by surgeons to order and receive  anatomical 3D models, generated from a CT or MRI scan.

Driving innovation that tangibly improves patient outcomes through minimally invasive surgical technology, with every decision evaluated through the lens of clinical benefit and patient safety.

Patient-Centered Innovation

Creating meaningful impact in healthcare by developing technologies that help doctors change lives, giving employees a sense of purpose and the opportunity to contribute to life-saving innovations.

Purpose & Impact

Fostering a culture where diverse teams collaborate without egos, bringing together expertise in robotics, software, clinical science, and medical device development to solve complex challenges.

Collaboration & Inclusion

Embracing complex technical and clinical challenges as opportunities for breakthrough innovation, maintaining excitement about advancing the boundaries of what's possible in surgery.

Innovation Through Challenges

Operating with humility, staying grounded in reality, and maintaining a learning mindset to continuously improve technology, processes, and clinical outcomes based on real-world evidence.

Humility & Continuous Learning

Intuitive Surgical is the global leader in robotic-assisted surgery, pioneering minimally invasive surgical solutions through its flagship da Vinci Surgical System and Ion endoluminal platform. With over 10,700 systems installed worldwide and nearly 17 million procedures performed, the company revolutionizes surgery by combining advanced robotics, 3D visualization, and precision instruments to improve clinical outcomes.

Intuitive Surgical offers funding for technology research: Deadline June 5

Patient Dies After Undertrained Surgeon Uses Intuitive Surgical's Da Vinci

How Intuitive Surgical Turned Medical Sci-Fi Into Reality

Monopoly lawsuit against surgical robot company Intuitive is moving to trial

Hospitals are taking on “Intuitive Surgery,” a surgical robot monopoly

Gary S. Guthart

CEO & Member of the Board (transitioning to Executive Chair July 2025)

Dave Rosa

President (becoming CEO July 2025)

Jamie Samath

Chief Financial Officer, Executive Vice President & Head of Business Technology

Gary Loeb

General Counsel & Chief Compliance Officer

Bob DeSantis

Executive Vice President & Chief Strategy and Corporate Operations Officer

Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S., 1,199 in Europe, 1,050 in Asia, and 342 in the rest of the world. Intuitive Surgical first appeared on the Fortune 500 in 2024 at number 497; in 2025 the company rose to number 459 overall and ranked 43rd within the healthcare sector.

https://en.wikipedia.org/wiki/Intuitive_Surgical

The fifth-generation multiport robotic surgical system featuring revolutionary Force Feedback technology that enables surgeons to feel tissue forces, over 10,000x the computing power of previous generations, improved ergonomics, and real-time surgical insights. FDA cleared in March 2024 and CE Mark approved in July 2025 for minimally invasive procedures across multiple specialties.

da Vinci 5 Surgical System

Fourth-generation multiport system with laser targeting, overhead instrument architecture, and enhanced reach for multi-quadrant surgery. The Xi enables complex procedures including colorectal, thoracic, and gynecologic surgeries with improved access and flexibility. Features high-definition 3D visualization and wristed instruments for precision dissection.

da Vinci Xi Surgical System

Fourth-generation system designed to provide advanced robotic-assisted surgery capabilities at a more accessible price point. The X system offers high-definition 3D vision, integrated table motion, and comprehensive instrumentation for general, urologic, and gynecologic procedures.

da Vinci X Surgical System

Single-port robotic system enabling surgery through one small incision, typically 2.5cm or less. SP technology is designed for urologic procedures (prostatectomy, partial nephrectomy) and transoral robotic surgery for head and neck procedures. Reduces scarring and recovery time compared to traditional approaches.

da Vinci SP (Single Port) Surgical System

Robotic-assisted bronchoscopy platform for minimally invasive lung biopsy featuring an ultra-thin, ultra-maneuverable catheter that navigates deep into the peripheral lung. Ion provides unprecedented stability for precision biopsy of suspicious nodules, enabling earlier lung cancer detection and diagnosis.

Ion Endoluminal System

Comprehensive portfolio of wristed surgical instruments designed specifically for da Vinci systems, featuring seven degrees of freedom that exceed the natural range of the human wrist. Instruments include scissors, graspers, needle drivers, vessel sealers, staplers, and specialized tools for various surgical specialties.

EndoWrist Instruments

Integrated fluorescence imaging technology that enables surgeons to visualize blood flow and tissue perfusion in real-time during surgery. Firefly helps identify critical anatomy including blood vessels, bile ducts, and ureters, improving surgical decision-making and patient safety.

Firefly Fluorescence Imaging

Advanced energy devices including vessel sealing technology and ultrasonic dissection tools integrated with da Vinci platforms. These instruments provide controlled tissue effects for hemostasis, cutting, and dissection across multiple surgical specialties.

da Vinci Energy Systems

Comprehensive training programs including simulation-based curricula, online learning modules, case observations, and hands-on proctored cases. Intuitive provides standardized training and credentialing for surgeons transitioning to robotic-assisted surgery across all specialties.

Surgical Training & Education Programs

Full-service support including preventive maintenance, remote diagnostics, technical support, system upgrades, and rapid response field service. Service contracts provide predictable uptime and ensure optimal system performance throughout the product lifecycle.

Service & Support Programs

The FDA cleared Intuitive's next-generation da Vinci 5 multiport robotic system featuring Force Feedback technology, over 10,000x the computing power of previous systems, and enhanced ergonomics. The revolutionary system enables surgeons to measure and feel subtle forces exerted on tissue during surgery, representing the biggest generational leap in da Vinci technology evolution.

Intuitive Announces da Vinci 5 FDA Clearance - Fifth-Generation Robotic System

Intuitive Surgical appeared on the Fortune 500 list for the first time, ranking #497 among America's largest companies. The milestone recognition reflects the company's growth to $8.35 billion in annual revenue and leadership position in the rapidly expanding surgical robotics market. Intuitive was among 14 companies making their Fortune 500 debut in 2024.

Intuitive Surgical Makes Fortune 500 Debut at #497

The da Vinci 5 surgical system received CE Mark approval (EU MDR certification) on July 2, 2025, enabling commercial sales across Europe for adult and pediatric minimally invasive endoscopic procedures. This regulatory milestone follows the FDA clearance in March 2024 and opens major international markets for the revolutionary robotic surgery platform with Force Feedback technology.

Intuitive's da Vinci 5 Receives European CE Mark Approval

Intuitive announced that Dave Rosa will become CEO effective July 1, 2025, succeeding Gary Guthart who will transition to Executive Chair of the Board. Rosa, a 29-year company veteran who joined as the ninth employee in 1996, brings deep institutional knowledge and strategic vision to lead Intuitive's next chapter of innovation and growth in robotic surgery.

Intuitive Announces CEO Transition - Dave Rosa to Become CEO

Intuitive unveiled new FDA-cleared software capabilities for da Vinci 5 designed to enhance surgeon and hospital efficiency through real-time surgical insights. The Force Gauge, In-Console Video Replay, and Network CCM features provide surgeons with enhanced feedback during procedures and enable immediate review of surgical technique without leaving the console.

Intuitive Introduces Real-Time Surgical Insights for da Vinci 5

The FDA cleared the da Vinci Single Port (SP) surgical system for transanal local excision and resection procedures. This expanded indication enables colorectal surgeons to perform minimally invasive removal of rectal lesions through natural orifices using single-port robotic technology, further expanding the clinical applications of Intuitive's surgical platforms.

Intuitive Announces FDA Clearance for da Vinci SP Transanal Procedures

Intuitive Surgical reported stellar Q2 2025 financial results with procedure volume growth of 17% year-over-year, driven by strong adoption of da Vinci systems across all major surgical specialties. The company's installed base exceeded 10,700 systems globally with approximately 2.68 million procedures performed in 2024. Revenue growth and margin expansion reflect the success of Intuitive's recurring revenue model from instruments and service.

Intuitive Reports Strong Q2 2025 Performance with 17% Procedure Growth

He developed the surgery. He trained the surgeons.  Was paid as a janitor

AIOStreams v2 is HERE! 🎉 Your Stremio Experience, Unified &amp; Supercharged - A Complete Rewrite!

The insane growth of Intuitive Surgical

is intuitive a top tier company?

Intuitive Surgical Verbal to Written Offer

IBM vs Intuitive Surgical vs Visa

$ISRG — Intuitive Surgical sits on $9B cash with zero debt. The balance sheet is funding a decade of procedure growth that nobody is fully pricing.

What are yall thoughts working at Intuitive Surgical?

Has anyone heard back from Intuitive Surgical for their Summer 2026 Intern roles?

Intuitive Surgical. Any advice?

MedicalDevices

HistoryUncovered

StremioAddons

internships

investing_discussion

cscareerquestions

MechanicalEngineering

INTUITIVE SURGICAL INC

Orthopedic, Prosthetic & Surgical Appliances & Supplies

John Freund, Frederic Moll, and Robert Younge founded Intuitive Surgical after writing a business plan and raising initial venture capital. The company was established to commercialize surgical robotics research conducted at SRI International, with the vision of enabling minimally invasive surgery through advanced robotic technology.

Company Founded

Intuitive completed development of its first prototype surgical robot called 'Lenny,' which was ready for clinical testing. This milestone validated the technical feasibility of robotic-assisted minimally invasive surgery and paved the way for regulatory approvals.

Prototype 'Lenny' System Ready

Intuitive began marketing the da Vinci system in Europe while awaiting FDA approval in the United States. The European launch provided early clinical validation and revenue to support further development and commercialization efforts.

European Marketing Launch

Intuitive Surgical went public on June 13, 2000, with an IPO price of $9 per share (split-adjusted $2), raising $46 million to fund commercialization. The company opened at the IPO price with 116 employees and has since delivered over 9,800% returns to shareholders.

Initial Public Offering

The FDA approved the da Vinci Surgical System for general laparoscopic surgery, marking the first regulatory clearance for robotic-assisted surgery in the United States. This approval enabled commercial sales and clinical adoption of the revolutionary technology.

FDA Approval for General Laparoscopic Surgery

The FDA cleared da Vinci for prostate surgery, opening the urology market which would become one of the largest applications for robotic surgery. Robotic prostatectomy became a key driver of da Vinci system adoption worldwide.

FDA Approval for Prostate Surgery

Intuitive Surgical and Computer Motion agreed to merge, ending litigation between the companies and consolidating the robotic surgery market. The merger strengthened Intuitive's intellectual property portfolio and market position.

Merger with Computer Motion

Intuitive launched the second-generation da Vinci S system with improved visualization, enhanced instruments, and better ergonomics. The S system accelerated clinical adoption and expanded the range of procedures performed robotically.

da Vinci S System Launch

The third-generation da Vinci Si system was released at approximately $1.75 million, featuring high-definition 3D vision, dual-console capability for teaching, and improved surgical instruments. The Si became the workhorse system driving global adoption.

da Vinci Si System Launch

Gary Guthart, a 27-year company veteran who contributed to the original da Vinci development at SRI International, was promoted to CEO. Under his leadership, Intuitive would grow from a niche player to a Fortune 500 company and global leader in surgical robotics.

Gary Guthart Named CEO

Intuitive introduced the fourth-generation da Vinci Xi system with laser targeting, overhead instrument architecture, and improved reach for multi-quadrant surgery. The Xi enabled more complex procedures and expanded clinical applications.

da Vinci Xi System Launch

Intuitive launched the da Vinci SP (Single Port) system, enabling surgery through a single small incision. SP technology opened new minimally invasive approaches for urology and transoral procedures, further reducing patient trauma.

da Vinci SP Single-Port System Launch

Intuitive introduced the Ion robotic-assisted bronchoscopy platform for lung biopsy procedures. Ion represents Intuitive's expansion beyond da Vinci into new clinical areas, targeting early lung cancer detection with an ultra-maneuverable catheter system.

Ion Endoluminal System Launch

By year-end 2021, Intuitive had an installed base of 6,730 da Vinci systems worldwide, representing significant market penetration in hospitals and surgical centers across 72 countries.

Reached 6,730 Installed Systems Globally

The FDA cleared the fifth-generation da Vinci 5 system on March 14, 2024. Da Vinci 5 features revolutionary Force Feedback technology, over 10,000x the computing power of Xi, enhanced ergonomics, and real-time surgical insights—representing the biggest generational leap in da Vinci evolution.

da Vinci 5 FDA Clearance

Intuitive Surgical made its debut on the Fortune 500 list, ranking #497 with annual revenue of $8.35 billion. This milestone recognition positions Intuitive among America's largest and most successful companies.

Fortune 500 Debut

Intuitive's da Vinci systems were used to perform approximately 2.68 million surgical procedures in 2024, representing 17% year-over-year growth. The company has now facilitated nearly 17 million total procedures since inception.

Surpassed 2.68 Million Procedures Annually

Intuitive announced on May 15, 2025, that Dave Rosa would become CEO effective July 1, 2025, succeeding Gary Guthart who will transition to Executive Chair. Rosa, the company's ninth employee with 29 years of service, brings deep institutional knowledge to lead Intuitive's next chapter of growth.

Dave Rosa Named CEO

The da Vinci 5 system received CE Mark approval (EU MDR certification) on July 2, 2025, enabling commercial sales across Europe for adult and pediatric minimally invasive endoscopic procedures. This regulatory milestone opens major international markets for the revolutionary system.

da Vinci 5 CE Mark Approval

Intuitive announced new FDA-cleared software capabilities for da Vinci 5 in September 2025, including Force Gauge, In-Console Video Replay, and Network CCM features. These innovations deliver real-time surgical insights to enhance surgeon and hospital efficiency.

Oura vs Intuitive Surgical

Oura

About

Intuitive Surgical

About

Also Compare

Track AI Visibility in Real Time